Th17细胞与多发性硬化/实验性自身免疫性脑脊髓炎
被引量:3
Th17 cells and multiple sclerosis/experimental autoimmune encephalomyelitis
摘要
多发性硬化(multiple sclerosis,MS)及其理想动物模型实验性自身免疫性脑脊髓炎(experimental autoimmune encephalomyelitis, EAE)是主要累及中枢神经系统的自身免疫性疾病。
出处
《中华神经医学杂志》
CAS
CSCD
北大核心
2010年第7期751-753,共3页
Chinese Journal of Neuromedicine
参考文献22
-
1Gran B,Zhang GX,Yu S,et al.IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis:evidence for redundancy in the EL-12 system in the induction of central nervous system autoimmune demyelination[J].J immunol,2002,169(12):7104-7110.
-
2Cua DJ,Sherlock J,Chen Y,et al.Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain[J].Nature 2003,421(6924):744-748.
-
3Yang XO,Pappu BP,Nurieva R,et al.T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma[J].Immunity,2008,28(1):29-39.
-
4Chen Z,Laurence A,Kanno Y,et al.Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells[J].Proc Natl Acad Sci U S A,2006,103(21):8137-8142.
-
5Huber M,Brü stle A,Reinhard K,et al.IRF4 is essential for EL-21-mediated induction,amplification,and stabilization of the Th17 phenotype[J].Proc Natl Acad Sci U S A,2008,105(52):20846-20851.
-
6Zhou L,Ivanov II,Spolski R,et al.IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways[J].Nat Immunol,2007,8(9):967-974.
-
7Ogura H,Murakami M,Okuyama Y,et al.Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction[J].Immunity,2008,29(4):628-636.
-
8Coquet JM,Chakravarti S,Smyth MJ,et al.Cutting edge:IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis[J].J Immunol,2008,180(11):7097-7101.
-
9Sonderegger I,Kisielow J,Meier R,et al.IL-21 and EL-21 R are not required for development of Th17 cells and autoimmunity in vivo[J].Eur J Immunol,2008,38(7):1833-1838.
-
10Veldhoen M,Hocking RJ,Flavell RA,et al.Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis,but chronic inflammation is needed to sustain disease[J].Nat Immunol,2006,7(11):1151-1156.
同被引文献34
-
1Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis[J]. Lancet Neurol, 2005, 4 (5): 281-288.
-
2Mancardi G, Hart B, Roccatagliata L, et al. Demyelination and axonal damage in a non-human primate model of multiple sclerosis [J]. J Neurol Sci, 2001, 184(1): 41-49.
-
3Bitsch A, Schuchardt J, Bunkowski S, et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation[J]. Brain, 2000, 123(Pt 6): 1174-1183.
-
4Kuhlmann T, Lingfeld G, Bitsch A, et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time[J]. Brain, 2002, 125(Pt 10): 2202-2212.
-
5Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" [J]. Ann Neurol, 2005, 58(6): 840-846.
-
6Kume A, Isikay IC, Karlioguz K, et at. A clinically isolatedsyndrome: a challenging entity: multiple sclerosis or collagen tissue disorders: clues for differentiation[J]. J Neurol, 2008, 255 (11): 1625-1635.
-
7Brettschneider J, Maier M, Arda S, et al. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis[J]. Mult Scler, 2005, 11(3): 261-265.
-
8Colucci M, Roccatagliata L, Capello E, et al. The 14-3-3 protein in multiple sclerosis: a marker of disease severity [J]. Mult Scler, 2004, 10(5): 477-481.
-
9Guimaraes I, Cardoso MI, S6 MJ. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis[J]. Mult Scler, 2006, 12(3): 354-356.
-
10Petzold A, Eikelenboom MJ, Gveric D, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations[J]. Brain, 2002, 125(Pt 7): 1462-1473.
引证文献3
-
1麦卫华,胡学强,陆正齐,彭福华,王玉鸽.多发性硬化、临床孤立综合征患者脑脊液β-淀粉样肽水平及其意义研究[J].中华神经医学杂志,2011,10(7):683-687. 被引量:1
-
2付红梅,王寅旭,王晓明,罗家明.IL-17F及IL-17A基因多态性与中国四川汉族人群多发性硬化的相关性[J].中国神经免疫学和神经病学杂志,2015,22(1):12-15. 被引量:3
-
3王晓庆,刘建春,田倩倩,郭文娟,李艳花,刘春云,杨春彦,马存根.芍药苷对细胞免疫调节作用的研究进展[J].中华中医药学刊,2016,34(6):1306-1308. 被引量:20
二级引证文献24
-
1杜雅平,韩军,焦晓明,王晓暄.TNFAIP3基因多态性与变应性鼻炎遗传易感性的关联性研究[J].标记免疫分析与临床,2016,23(8):899-902. 被引量:3
-
2王小国.芍药基因组DNA不同提取方法的比较及PCR验证[J].现代园艺,2016,39(18):5-6.
-
3吴修红,孙晓兰,胡妮娜,杨东霞,张金琦,王旭,孙泽,赵闯,孙晖.赤芍功效物质基础研究进展[J].中医药信息,2017,34(2):120-122. 被引量:47
-
4田倩倩,李艳花,尉杰忠,王晓庆,张红珍,刘建春,郭文娟,刘春云,杨春彦,肖保国,马存根.补阳还五汤对实验性自身免疫性脑脊髓炎单核巨噬细胞的免疫调控作用[J].中国病理生理杂志,2017,33(2):200-207. 被引量:11
-
5郝乘仪,冯波,郭淑英,朱鹤云,昌盛.基于高效液相色谱-二极管阵列检测法测定妇科分清丸中8个成分的含量[J].药物分析杂志,2017,37(5):803-811.
-
6陈永财,钱江辉,王彬辉,沙先谊,翁金月.桂枝-白芍药对不同比例配伍对芍药苷在大鼠体内药动学的影响[J].中国临床药理学与治疗学,2017,22(11):1237-1243. 被引量:16
-
7魏学军,林先燕,赵鸿宾,李雪营,刘汇丽.Box-Behnken设计-效应面法优选四物汤活性成分的提取工艺[J].黔南民族医专学报,2017,30(4):235-238. 被引量:4
-
8刘晨阳,于顾然.芍药苷对纤维状Aβ1-42介导的血脑屏障体外模型损伤的影响[J].辽宁中医杂志,2018,45(1):163-166. 被引量:5
-
9钟晓南,胡学强.特发性炎性脱髓鞘疾病研究进展[J].中国现代神经疾病杂志,2018,18(2):99-109. 被引量:3
-
10魏学军,林先燕,李雪营,赵鸿宾,何鑫.综合评分-正交试验法优选四物汤中活性成分的提取工艺[J].亚太传统医药,2018,14(5):42-44. 被引量:2
-
1纪宁,尉杰忠,马存根,米亚英.雌激素在实验性自身免疫性脑脊髓炎中的保护作用[J].中华神经医学杂志,2006,5(12):1274-1276. 被引量:6
-
2石秋艳,田广平,高敬华,孙原,张春阳,范亚霞.阿托伐他汀对实验性自身免疫性脑脊髓炎大鼠单核细胞趋化蛋白-1表达的影响[J].中国煤炭工业医学杂志,2013,16(6):975-977.
-
3贾荣艳.53例多发性硬化的MRI与临床[J].河北医学,2003,9(8):698-699. 被引量:2
-
4郭敏芳,张慧宇,刘华.骨髓间充质干细胞对EAE小鼠MMP-9的影响[J].人人健康,2016,0(8):4-4.
-
5王捷,马存根,纪宁,尉杰忠.他汀类药物在多发性硬化和实验性自身免疫性脑脊髓炎治疗中的应用[J].山西大同大学学报(自然科学版),2009,25(2):45-47. 被引量:2
-
6辛晋敏,马存根,梁丽云,马太花,尉杰忠.细胞间黏附分子-1在实验性自身免疫性脑脊髓炎大鼠中表达的动态变化及作用[J].中国神经免疫学和神经病学杂志,2006,13(2):77-81. 被引量:10
-
7脊髓疾病[J].国外科技资料目录(医药卫生),1998(10):168-168.
-
8刘红阳,吕志勤.多发性硬化临床进展[J].交通医学,2001,15(4):355-357.
-
9柳太云,姚晓黎,张成,曾缨,冯慧宇.多发性硬化154例临床分析[J].中国神经精神疾病杂志,2004,30(6):471-472. 被引量:4
-
10孙增强,李建川.多发性硬化并抑郁障碍58例临床分析[J].中国基层医药,2009,16(9):1654-1654. 被引量:1